These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20821212)

  • 1. The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.
    Oelzner P; Franke S; Lehmann G; Eidner T; Hein G; Wolf G
    Rheumatol Int; 2012 Jan; 32(1):199-206. PubMed ID: 20821212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
    Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
    Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
    Xu S; Wang Y; Lu J; Xu J
    Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
    Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
    Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females.
    Li X; Zuo X; Lu L; Xu R; Wang Y; Chang S; Wang Y; Luo P; Li G
    Front Endocrinol (Lausanne); 2024; 15():1442046. PubMed ID: 39351524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
    Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
    J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.
    Amer OE; Wani K; Ansari MGA; Alnaami AM; Aljohani N; Abdi S; Hussain SD; Al-Daghri NM; Alokail MS
    Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 35893092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
    Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes.
    Giuliani N; Sansoni P; Girasole G; Vescovini R; Passeri G; Passeri M; Pedrazzoni M
    Exp Gerontol; 2001 Mar; 36(3):547-57. PubMed ID: 11250125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
    Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
    Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.